Cargando…
The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alon...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285947/ https://www.ncbi.nlm.nih.gov/pubmed/24894120 http://dx.doi.org/10.1111/1755-5922.12083 |